Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 13, 2018
Three Falling Peaks on Teva Pharmaceuticals

Three Falling Peaks on Teva Pharmaceuticals

Teva Pharmaceuticals (NYSE: TEVA) has outperformed the vast majority of stocks over the past year. According to Investor Business Daily’s Relative Strength rating, Teva’s stock price has appreciated more than 94% of the stocks in its database over the past year. Unfortunately for shareholders, there is a pattern on the chart that suggests that the stock is ready to fall sharply in the coming month or so.

The pattern is known as a Three Falling Peaks pattern and it is highlighted with the three blue circles on the chart below. In this case, the three peaks have also formed the upper rail of a trend channel with the lows over the last three months connecting as well.

The stock dropped over 19% in three weeks from the August high to the September low and from the September high to the first October low. If the pattern plays out the same way and drops over 19% again, the stock would be under $19.50 this time around.

The fundamentals for Teva are also a factor as the company has lagged in its earnings and sales growth. The company gets a 22 on IBD’s EPS rating and that means that 78% of the companies in its database have experienced better earnings growth. The SMR rating for Teva is a D and that is below average as well.

Teva reported third-quarter earnings on November 2 and that report showed an earnings decline of 32% over last year and a sales drop of 19% from the same quarter of 2017.

Related Ticker: TEVA

Momentum Indicator for TEVA turns negative, indicating new downward trend

TEVA saw its Momentum Indicator move below the 0 level on July 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned negative. In of the 77 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for TEVA turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

TEVA moved below its 50-day moving average on July 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TEVA crossed bearishly below the 50-day moving average on June 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEVA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TEVA broke above its upper Bollinger Band on July 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TEVA entered a downward trend on June 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.413) is normal, around the industry mean (46.455). P/E Ratio (23.269) is within average values for comparable stocks, (100.443). Projected Growth (PEG Ratio) (0.889) is also within normal values, averaging (1.654). TEVA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.036). P/S Ratio (2.100) is also within normal values, averaging (116.256).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.02B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 14%. CPHI experienced the highest price growth at 50%, while SXTC experienced the biggest fall at -87%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 38%. For the same stocks of the Industry, the average monthly volume growth was 25% and the average quarterly volume growth was 27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 64
Price Growth Rating: 58
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
TEVA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Pharmaceuticals Generic
Address
124 Dvora HaNevi’a Street
Phone
+972 39148213
Employees
37851
Web
https://www.tevapharm.com
Interact to see
Advertisement
BitMine Immersion Technologies (BMNR) is set to report Q1 FY2026 earnings on January 16, 2026, with consensus estimates calling for EPS of $0.15 and revenue of approximately $79.3 million.
Bank of America (BAC) and Wells Fargo (WFC) will both report Q4 2025 earnings on January 14, 2026, creating a rare same-day, apples-to-apples comparison.
Citigroup (C) is set to report Q4 2025 earnings on January 14, 2026, making it the immediate catalyst in this comparison. HSBC Holdings (HSBC) will release its Full-Year 2025 results on February 25, 2026, positioning it as a medium-term earnings event.
Wells Fargo’s quarterly results carry broader significance because the bank serves as a key indicator of U.S. consumer and commercial banking conditions. Its earnings often influence sentiment toward the entire large-cap banking sector. After a stretch of improved market conditions and stronger capital markets activity, investors are looking for confirmation that profit momentum is sustainable rather than driven by a single favorable quarter.
M&T Bank (MTB) is expected to deliver Q4 2025 EPS of $4.44–$4.46, representing roughly 13% year-over-year growth, driven by improving net interest income as funding costs decline. PNC Financial Services Group (PNC) is projected to post Q4 EPS of $4.19–$4.23, supported by about 1.5% sequential NII growth from rate relief and steady loan demand. U.S. Bancorp (USB) is forecast to earn $1.19 per share, an 11.2% annual increase, with revenues estimated at $7.33 billion, up 5%.
Dash (DASH.X) has ignited the crypto market with a powerful mid-January 2026 breakout, rallying more than 125% in a single week and decisively outperforming fellow privacy coins such as Monero and Zcash. The surge was fueled by a sharp short squeeze that wiped out nearly $4.9 million in bearish positions, alongside a major catalyst: Dash’s integration with Alchemy Pay, enabling direct fiat purchases across 173 countries.
The Schwab U.S. Small-Cap ETF (SCHA) is holding firm near the $28 level as 2026 begins, even as broader markets remain volatile. While short-term price action has been uneven, underlying signals suggest the ETF may be setting up for a meaningful breakout as interest-rate cuts revive small-cap equities. Technical models highlight an unusually favorable risk-reward profile—up to 22:1—with long-term momentum strengthening despite near-term consolidation.
The Vanguard Small-Cap Value ETF (VB) is quietly standing out in what has been a turbulent start to 2026. While many small-cap segments have struggled, VB has shown notable resilience, including a 3.2% jump on January 14, driven by renewed buying interest in undervalued industrial and financial stocks. This divergence from broader small-cap weakness suggests early signs of mean reversion, particularly as incoming economic data points toward eventual interest-rate relief.
The Vanguard Russell 2000 ETF (VTWO) has entered 2026 with renewed technical strength, breaking through several key indicators that suggest a potential trend reversal. On January 2, 2026, VTWO’s Momentum Indicator moved decisively above zero, a signal often associated with the early stages of bullish cycles. This followed an earlier technical milestone in December 2025, when the 10-day moving average crossed above the 50-day, drawing attention from momentum and swing traders alike.
CAOS, the trading ticker for IRIS Energy Limited, is emerging as a standout performer in early 2026 as two powerful trends converge: Bitcoin’s renewed surge and explosive demand for AI-ready data infrastructure. As Bitcoin pushes higher and investors hunt for leveraged exposure to both crypto and artificial intelligence, CAOS has attracted increasing attention from retail and quantitative traders alike.
Prologis (PLD), the world’s largest logistics-focused REIT, reported fourth-quarter and full-year 2025 earnings on January 21, 2026, capping a standout year for the industrial real estate sector. Demand for modern logistics facilities remains elevated as e-commerce expansion and supply chain reconfiguration continue to reshape global distribution networks.
The Travelers Companies, Inc.(TRV), a major player in the property and casualty insurance market, reported fourth-quarter 2025 results on January 21, 2026, closing out a year marked by underwriting discipline despite volatile weather activity and pricing pressures. The results underscore Travelers’ ability to generate strong profitability while navigating challenges in personal insurance lines and heightened catastrophe risk.
FingerMotion, Inc. (NASDAQ: FNGR) reported fiscal third-quarter 2026 results on January 15, 2026, triggering a sharp selloff as investors reacted to a steep revenue decline and widening losses. Shares fell roughly 32% following the release after the mobile services provider disclosed a 32% year-over-year drop in revenue and a net loss of $1.67 million for the quarter ended November 30, 2025.
CSX Corporation, a major U.S. East Coast rail operator, reports fourth-quarter 2025 earnings after market close today, marking the end of a year characterized by uneven freight recovery. Comparing CSX with Canadian Pacific Kansas City (CP), now a transcontinental operator following its 2023 merger, highlights contrasting strategies within the North American rail sector.
Procter & Gamble (PG) reports fiscal Q2 2026 earnings on January 22, with consensus expecting modest revenue growth amid commodity and tariff pressures. EPS is forecast at ~$1.87, slightly below last year’s $1.88. Colgate-Palmolive (CL) is set to release Q4 2025 earnings on January 30, while Unilever (UL) reports full-year 2025 results on February 12.
CSX (NASDAQ: CSX) reports Q4 2025 earnings after market close on January 22, 2026, with consensus EPS ~$0.42 and revenue ~$3.57 billion. Union Pacific (NYSE: UNP) follows on January 27, with EPS expected near $2.89 and revenue around $6.15 billion. Norfolk Southern (NYSE: NSC) closes the week on January 29, with consensus EPS ~$2.77.
The SPDR S&P Aerospace & Defense ETF (XAR) has surged to a new 52-week high above $281 this week, climbing 21% month-to-date and 20% year-to-date through January 2026. The rally, driven by robust sector momentum and a clean technical breakout, is outpacing broader indices like the S&P 500. XAR’s equal-weighted structure amplifies gains from top aerospace and defense holdings in missiles, aircraft, and space systems, attracting significant trader and institutional attention amid heightened geopolitical tensions.
The iShares U.S. Aerospace & Defense ETF (ITA) continues to attract trader attention, building on a remarkable 47.7% gain in 2025 amid rising defense budgets and heightened global security concerns. The ETF is approaching all-time highs, with top holdings such as GE Aerospace and RTX Corporation driving the rally. Traders are adding positions on dips while monitoring confirmation above key resistance levels near recent peaks, anticipating a potential technical breakout.
ProShares Ultra Gold (UGL), the leveraged ETF designed to deliver 2× the daily performance of gold futures, has climbed sharply this week as gold prices continue near historic levels. The ETF’s move reflects renewed inflows into gold-related products and heightened investor interest in safe-haven assets amid ongoing geopolitical and macroeconomic uncertainty. UGL’s price action closely mirrors the strong trend in gold futures, attracting short-term momentum trading even as the leveraged structure carries heightened risk.
Hubbell Incorporated (HUBB) reached an all-time high of $485.91 this week, reflecting strong buying interest in the industrial sector. The breakout comes amid mixed institutional activity—some funds trimming positions while others add new stakes—highlighting investor focus on HUBB’s multi-year rally.